Spruce Biosciences to Participate in June Investor Conferences

Rhea-AI Summary

Spruce Biosciences (NASDAQ: SPRB) announces participation in two investor conferences in June 2022. The Jefferies Healthcare Conference will take place from June 8-10, 2022, featuring a company presentation on June 8 at 4:00 PM ET. The JMP Securities Life Sciences Conference follows on June 15-16, 2022, highlighted by a fireside chat on June 16 at 11:30 AM ET. Webcasts of both events will be accessible via Spruce's investor relations website, with replays available for 30 days. Spruce is focused on therapies for rare endocrine disorders, including potential treatments for congenital adrenal hyperplasia.

SAN FRANCISCO--(BUSINESS WIRE)-- Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that company management will participate in two upcoming investor conferences taking place in June.

• Jefferies Healthcare Conference
  Date: June 8-10, 2022
  Format: Company presentation (June 8, 2022 at 4:00pm ET) and 1x1 meetings
  

• JMP Securities Life Sciences Conference
  Date: June 15-16, 2022
  Format: Fireside chat (June 16, 2022 at 11:30am ET) and 1x1 meetings

Interested parties can access the webcast for each conference presentation from the Events section of the company’s investor relations website at https://investors.sprucebiosciences.com. A replay of the webcasts will be available after the conclusion of the live presentations for approximately 30 days.

About Spruce Biosciences

Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. Spruce is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy for patients suffering from classic congenital adrenal hyperplasia (CAH). Classic CAH is a serious and life-threatening disease with no known novel therapies approved in approximately 50 years. Spruce is also developing tildacerfont for women suffering from polycystic ovary syndrome (PCOS) with primary adrenal androgen excess. To learn more, visit www.sprucebiosciences.com and follow us on Twitter @Spruce_Bio, LinkedIn, Facebook and YouTube.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220601006104/en/

Media Contact

Will Zasadny

Canale Communications

(619) 961-8848

will.zasadny@canalecomm.com

media@sprucebiosciences.com

Investors

Xuan Yang

Solebury Trout

(415) 971-9412

xyang@soleburytrout.com

investors@sprucebiosciences.com

Source: Spruce Biosciences, Inc.

FAQ

What conferences is Spruce Biosciences participating in June 2022?

Spruce Biosciences is participating in the Jefferies Healthcare Conference and the JMP Securities Life Sciences Conference.

When is Spruce Biosciences' presentation at the Jefferies Healthcare Conference?

The presentation at the Jefferies Healthcare Conference is on June 8, 2022, at 4:00 PM ET.

What is the date of the fireside chat during the JMP Securities Life Sciences Conference?

The fireside chat is scheduled for June 16, 2022, at 11:30 AM ET.

Where can I access the webcasts for the investor conferences?

Webcasts for the conferences can be accessed from the Events section of Spruce's investor relations website.

What is Spruce Biosciences' focus in biopharmaceuticals?

Spruce Biosciences focuses on developing therapies for rare endocrine disorders, particularly congenital adrenal hyperplasia.